7.Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol. 2020 Dec;95(12):1542-1552. ...
侯明教授 IWG和ASH分别在2019年更新了《原发性免疫性血小板减少症调查和管理的最新国际共识报告》3和《美国血液学会2019年免疫性血小板减少症指南》4,中华医学会血液学分会血栓与止血学组则在2020年更新了《成人原发免疫性血小板减少症诊断与治疗...
炒股第一步,先开个股票账户 今日,Sanofi 在今年美国血液学会(ASH)年会的摘要中公布了其潜在“first-in-class”口服BTK抑制剂rilzabrutinib在ITP 3期试验中的阳性结果:23%的免疫性血小板减少症(ITP)成年患者达到了主要终点,而安慰剂组无一患者达标。赛诺菲正为该疗法用于ITP治疗向FDA提交监管申请做准备。 Rilzabrut...
**Treatment-free remission definition: Maintained all platelet counts at≥50 x 109/L for≥6 months without any ITP treatment.8 2L, second line; 3L, third line; ITP, immune thrombocytopenia; RWE, real-world evidence; TFR, treatment-free remission. Study Design8 Choose Nplate®first when your...
11/5,Sanofi$赛诺菲-安万特(SNY)$ 周二公布了其用于治疗免疫性血小板减少症(ITP)的关键试验rilzabrutinib的详细结果。此前在4月,Sanofi首次披露了这款BTK抑制剂在III期LUNA 3研究中达到了主要终点。当时,这家法国制药公司宣布计划在年底前向美国和欧洲提交监管申请。若
Serologic testing is something that has been discussed for a long time and was a subject of an ASH Clinical Practice Guidelines report in 2011. I wonder if it’s going to find more prominence over time. One doesn't need to do a bone marrow examination, but if there are other ...